EGFR and non-small cell lung carcinoma: The rapid development of EGFR‐TKIs during the past two decades from the initial 1st generation (e.g., gefitinib and erlotinib) to 2nd generation (e.g., afatinib) and current 3rd generation (e.g., osimertinib; also named AZD9291 or TAGRISSO) agents as a consequence of battling against the inevitable issue of acquired resistance has substantially contributed to the improved quality of life and prolonged survival of patients with EGFR mutant (EGFRm NSCLC.